Global Anti-TIGIT Antibody Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti-TIGIT Antibody Market Research Report 2024
A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity.
According to Mr Accuracy reports new survey, global Anti-TIGIT Antibody market is projected to reach US$ 787.1 million in 2029, increasing from US$ 324.8 million in 2022, with the CAGR of 13.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-TIGIT Antibody market research.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-TIGIT Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Anti-TIGIT Antibody report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Anti-TIGIT Antibody market is projected to reach US$ 787.1 million in 2029, increasing from US$ 324.8 million in 2022, with the CAGR of 13.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Anti-TIGIT Antibody market research.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-TIGIT Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Anti-TIGIT Antibody report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices